MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab

Trial Profile

MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Daratumumab (Primary) ; Durvalumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms FUSION-MM-005
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Mar 2018 This study has been completed in Italy (End date: 2017-12-04).
    • 02 Mar 2018 This study has been completed in Netherlands (End date: 2017-12-04).
    • 31 Jan 2018 This study has been completed in Sweden (End date: 2017-12-04).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top